Sartorius Stedim Biotech rocks single-use bioreactor market
Aubagne/Frankfurt – Sartorius Stedim Biotech SA has substantially expanded its technology portfolio as a supplier for the bio-pharmaceutical industry. At the ACHEMA, the world´s largest trade fair for bioprocess equipment, the company presented two new prototypes of single-use bioreactors that make use of novel mixing technologies co-developed with Bayer Technology Services GmbH (BTS) and Swiss ExcellGene SA. The disposable systems are a major driver of growth for suppliers of the biopharmaceutical industry, because they offer cheaper and more flexible production possibilties than stainless steel fermentors that need time-consuming and expensive cleaning validation.
With the new bioreactors, which are specially designed for the manufacture of monoclonal antibodies, recombinant proteins and vaccines, Sartorius attacks competitors like Thermo Fisher, who offer single use stirred bioreactors or GE Healthcare, who markets shaked reusable plastic bags for mid-scale biomanufacture.
„Based on this comprehensive technology platform, we are taking a huge step forward towards achieving our goal of becoming the global market leader in single-use bioreactors," said Dr. Oscar-Werner Reif, Member of Sartorius Stedim Biotech's Board of Directors.
From 2010, the company plans to extend its technology portfolio, which already comprises stirred and shaked bioreactor types, by the novel systems. The rotationally oscillating bioreactor, co-developed with Bayer Schering Pharma AG, allows for surface or membrane gasing of sensitive cultures. The orbital shake bioreactor, developed with ExcellGene, allows for screening of media and cultivation conditions. Each of the four agitation technologies offers user specific advantages contingent upon the cells to be produced, the scale-up level of the cell cultures and additional process parameters. Despite financial crisis, ACHEMA achieved its second best result ever, regarding the number of exhibitors.